The BLA completion guidance to Q4 2026 and upcoming PIVOT-006 data in H1 2026 are the key catalysts. The CORE-008 Cohort CX data at AUA on May 16 could provide early read on combination therapy. The $1.1B cash runway through 2029 removes near-term financing risk. Monitor the PIVOT-006 topline for potential approval expansion into intermediate-risk NMIBC.
CGON drugs
CGON drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · May 8 $69.62entry
- T+1 · 6mo ago −0.43%α −0.66% · $69.32
- T+5 · 6mo ago −0.12%α −1.59% · $69.54
- T+20 · 5mo ago −22.84%α −22.86% · $53.72
- T+60 · 3mo ago +2.56%α −2.28% · $71.40
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
CG Oncology reported Q1 2026 results with a net loss of $0.71 per share, slightly wider than the $0.45 loss a year ago, but the headline is the BLA completion timeline for cretostimogene in BCG-unresponsive NMIBC now guided to Q4 2026, with Phase 3 PIVOT-006 topline data expected in H1 2026. The company raised $391.4M via ATM in Q1, boosting cash to $1.1B, sufficient through 2029, and reported first commercial revenue of $1.07M. The stock will move on the BLA timeline clarity and upcoming PIVOT-006 data readout.
Key Financial Metrics
Key Facts
- BLA completion for cretostimogene in HR BCG-unresponsive NMIBC guided to Q4 2026 (previously no specific timeline)
- Phase 3 PIVOT-006 topline data in intermediate-risk NMIBC expected H1 2026
- First results from CORE-008 Cohort CX (cretostimogene + gemcitabine) to be presented at AUA May 16, 2026
- Net loss of $60.2M ($0.71/share) vs $34.5M ($0.45/share) in Q1 2025
- Cash, cash equivalents and marketable securities of $1.1B, up from $742.2M at Dec 2025
- Raised ~$391.4M via ATM facility in Q1 2026 from 6.94M shares
- First commercial and development revenue of $1.07M reported (vs $0 in Q1 2025)
- R&D expenses increased to $43.7M from $27.5M; G&A expenses increased to $20.8M from $14.8M
Financial Impact
Net loss widened to $60.2M from $34.5M; cash position strengthened to $1.1B from $742.2M; first commercial revenue of $1.07M reported
Risk Factors
- PIVOT-006 topline data may miss efficacy endpoints, delaying label expansion
- BLA submission could face CMC delays beyond Q4 2026 guidance
- Widening net loss trajectory with no near-term profitability expected
- Competitive landscape in NMIBC (Keytruda, other oncolytic viruses)
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3291055 |
Track record
25 reports on CGON
6 of 7 bullish or bearish reports moved the stock their way by T+20. Best: +26.33% at T+20 after the Jun 12, 2026 report. 8 of 8 went positive at some point.
Filters
- Nov 16, 2026today 8-K Bullish 7/10 Entry $98.84 Now $84.78 −14.23% settles Dec 15
- Nov 16, 2026today Press Release Bullish 7/10 Entry $95.01 Now $84.78 −10.77% settles Dec 15
- Nov 6, 202610d ago 8-K Bearish 5/10 Entry $75.99 Now $84.78 −11.57% settles Dec 7
- Nov 6, 202610d ago Press Release Neutral 4/10 Entry $75.99 Now $84.78 +11.57% settles Dec 7
- Nov 3, 202613d ago Institutional Cluster Neutral 3/10 Entry $64.06 Now $84.78 +32.34% settles Dec 2
- Oct 19, 202628d ago 3 Neutral 2/10 Entry $61.93 Now $84.78 +36.90% settles Nov 17
- Oct 15, 20264w ago 144 Neutral 2/10 Entry $59.85 to $74.40 Now $84.78 +41.65% ▲ +24.31% +25.47% vs SPY
- Oct 12, 20265w ago Institutional Cluster Mixed 3/10 Entry $63.13 to $74.74 Now $84.78 +34.29% ▲ +18.39% +21.66% vs SPY
- Aug 6, 202614w ago Press Release Bearish 7/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
- Aug 6, 202614w ago 424B5 Bearish 6/10 Entry $74.85 to $74.33 Now $84.78 −13.27% ▲ +0.69% +1.29% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers